Extended Data Fig. 6: S. copri abundance levels in responders and non-responders in Mimic, Baruch, and Davar studies, and metabolomics analysis on patient plasma.

A, Patient-level median S. copri abundance (CPM) across timepoints in each interventional FMT study (Baruch, Davar, MIMic). B, Patient-level S. copri abundance among responders and non-responders in the MIMic cohort and C, the combined Baruch et al. and Davar et al. cohorts before and after FMT and anti-PD1 therapy. Each point represents a patient’s log10 (S. copri abundance in CPM + 1), averaged across samples collected at the same time point when applicable. n denotes the number of patients per group. Two-sided p-values were calculated using unpaired Wilcoxon rank-sum test with FDR correction. Boxplot bounds represent the 25th and 75th percentiles, with the central line representing the median and the whiskers representing the maximum or minimum values within 1.5 x interquartile range (IQR). Points outside this range are shown as outliers. Scatterplot of best change in tumor baseline vs. log2 of D, Isocitric acid and E, Stearoylcarnitine intensity. Spearman’s rank correlation indicated. F, Boxplots of isocitric acid showing significant differences between responder (n = 8) and non-responder (n = 8) patients at T5. Boxplot bounds represent the 25th and 75th percentiles, with the central line representing the median and the whiskers representing the maximum or minimum values within 1.5 x interquartile range (IQR). G, Kaplan-Meier plot showing progression-free survival (PFS) according to isocitric acid and H, Stearoylcarnitine intensity in plasma at T5. Statistical analysis was conducted using two-sided unpaired t-tests with Benjamini-Hochberg correction for multiple comparisons.